Pediatric oncologists are forced to adjust adult cancer treatments for childhood cancer due to insufficient specific therapies for children with cancer. To date, we only have six drugs developed and approved specifically for children with cancer, even though cancer is still the leading cause of death by disease in children. Moreover, though being "cured" of cancer, childhood cancer survivors often experience late effects, both physical and psychological, secondary to their cancer or associated with the treatment's toxicity. For these reasons, Oncoheroes Biosciences was born to only focus on developing new and better therapies for pediatric oncology.
Oncoheroes is thrilled to announce the investment of Fundación Olivares, a childhood cancer non-profit from Málaga (Spain) founded in 2010 to help childhood cancer families. It is the first time Fundación Olivares goes beyond assisting familiesby supporting pediatric cancer research and investing in a biotech company.
“It took us more than 10 years to find a research project as closely aligned to our philosophy as Oncoheroes Biosciences," stated Andrés Olivares, founder of Fundación Olivares. “The confidence conveyed, Oncoheroes’ team professionalism, and the fact that they are developing specific medicines for children were key in our decision-making process to join this project.”
Fundación Olivares offers comprehensive help to families affected by childhood cancer and other serious chronic diseases through different activities such as psychological support, physiotherapy, speech therapy, balance and Reiki techniques, nutrition, school support, among others.
“We are very pleased to end Childhood Cancer Awareness Month with the first childhood cancer organization outside the US joining this project,“ said Ricardo Garcia, Oncoheroes’ Co-Founder, and CEO. “We feel honored, and we want to thank Fundación Olivares for their trust and commitment to have an impact on pediatric drug development.”
